| abstract |
The present invention relates to a novel co-administration EGFR antibody used in preventing or treating cancer. The antibody of the present invention is specifically coupled with EGFR overexpressed in cancer cells (in particular, colon cancer), and is coupled with an epitope which is different from cetuximab. Compared to CDR sequences of conventional EGFR target antibodies, the antibody of the present invention has very low homogeneity, and thus the sequence thereof is unique. When the antibody of the present invention is co-administrated with cetuximab, cancer cells are killed through a remarkably improved cancer cell killing function. Thus, the antibody of the present invention is very effective in preventing or treating cancer (in particular, colon cancer). The excellence of a co-administration effect of the antibody of the present invention, without wishing to be bound by theory, is determined by considering that the antibody of the present invention is coupled with an epitope on EGFR which is different from cetuximab to control EGFR cooperatively with cetuximab. |